REGENXBIO Announces Dosing of First Patient in Phase I/II Trial of RGX-111 for the Treatment of Mucopolysaccharidosis Type I

– Trial will evaluate one-time, direct-to-CNS treatment for MPS I   – Second novel gene therapy for neurodegenerative disease program to be actively enrolling patients ROCKVILLE, Md. , Dec. 1, 2020 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking

No Comments

Comments are closed.

REGENXBIO Announces Dosing of First Patient in Phase I/II Trial of RGX-111 for the Treatment of Mucopolysaccharidosis Type I

– Trial will evaluate one-time, direct-to-CNS treatment for MPS I   – Second novel gene therapy for neurodegenerative disease program to be actively enrolling patients ROCKVILLE, Md. , Dec. 1, 2020 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking

No Comments

Comments are closed.